Digest Network Come funziona
Network
/
Società
Vi
Non verificato

ViiV Healthcare

Di cosa scriviamo

FarmaceuticaHIV, AIDS e malattie autoimmuniIndustriaMedicina - VarieSalute

20 comunicati stampa

Guarda tutti i comunicati
25/02/2026
Industria
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
25/02/2026
Eventi
Fiere
Industria
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
18/02/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Industria
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
17/02/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Salute
Medicina - Varie
ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
17/10/2025
Biotecnologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Sanità
Salute
Igiene alimentare
Medicina - Varie
Industria
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
15/10/2025
Sanità
Management
Farmaceutica
Pubblico Esercizio/Vendita al dettaglio
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Scienza
Assistenza all'Infanzia
Vetrine/Shopping
Salute
Industria
Analisi di mercato
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
09/10/2025
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Eventi
Fiere
ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
14/07/2025
HIV, AIDS e malattie autoimmuni
Farmaceutica
Salute
Analisi di mercato
Industria
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
14/07/2025
HIV, AIDS e malattie autoimmuni
Farmaceutica
Salute
Analisi di mercato
Industria
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
14/07/2025
HIV, AIDS e malattie autoimmuni
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0